PharmaShots | Incisive News in 3 Shots

Subscribe Now

IO Biotech

PharmaShots Interview: In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Metastatic Melanoma Trial Presented at AACR 2022

PharmaShots Interview: In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Met...

June 28, 2022

IO Biotech Reports First Patient Dosing of IO102-IO103 + Keytruda (pembrolizumab) in the P-III (IOB-013 / KN-D18) Trial as 1L Treatment of Advanced Melanoma

IO Biotech Reports First Patient Dosing of IO102-IO103 + Keytruda (pembrolizumab) in the P-III (IOB-013 / KN-D18) Trial as 1L Trea...

May 19, 2022

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

March 11, 2021

IO Biotech's IO102 + IO103 Receive the US FDA's Breakthrough Therapy Designation for Unresectable/ Metastatic Melanoma

IO Biotech's IO102 + IO103 Receive the US FDA's Breakthrough Therapy Designation for Unresectable/ Metastatic Melanoma

December 15, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us